Olema Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Olema Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- OLMA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001750284
- EIN
- 30-0409740
Board of directors
-
Andrew Rappaport · DirectorSince 2023
-
Cynthia M. Butitta · DirectorSince 2023
-
Cyrus Harmon · DirectorSince 2023
-
G. Walmsley Graham · DirectorSince 2023
-
Gorjan Hrustanovic · DirectorSince 2023
- Since 2023
-
J. Scott Garland · DirectorSince 2023
-
Mark N. Lampert · DirectorSince 2023
-
Prakash Raman · DirectorSince 2026
-
Sandra Horning · DirectorSince 2023
-
Sean Bohen · Director · PRESIDENT AND CEOSince 2023
-
Yi Larson · DirectorSince 2023
Chief executives
Sean Bohen
· PRESIDENT AND CEO
Dates unknown
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
73.4%
-
98.0%
-
98.3%
Board connections
7 of this board's directors also sit on 20 other boards.
- via Gorjan Hrustanovic and Mark N. Lampert
- via J. Scott Garland
- via Cynthia M. Butitta
- via Ian T. Clark
- via Prakash Raman
- via Cynthia M. Butitta
- via Ian T. Clark
- via J. Scott Garland
- via Sandra Horning
- via Ian T. Clark
- via Ian T. Clark
- via Mark N. Lampert
- via Ian T. Clark
- via J. Scott Garland
- via Sandra Horning
- via Mark N. Lampert
- via Sandra Horning
- via Ian T. Clark
- via Ian T. Clark
- via Cynthia M. Butitta
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $24,739,344
- 25 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmon Director | Open-market sale | −12,500 | $11.71 | $146,425 |
| Jul 23, 2026 | Cyrus Harmon Director | Open-market sale | −12,500 | $11.58 | $144,738 |
| Mar 4, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Option exercise | +25,000 | $4.37 | $109,250 |
| Mar 4, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Open-market sale | −24,767 | $24.25 | $600,600 |
| Mar 4, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Open-market sale | −233 | $24.69 | $5,753 |
| Mar 3, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Option exercise | +15,000 | $4.37 | $65,550 |
| Mar 3, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Open-market sale | −15,000 | $23.01 | $345,150 |
| Feb 2, 2026 | Austin Sasha Lu Officer (VP of Finance and Controller) | Grant or award | +11,700 | — | — |
| Jan 20, 2026 | Cyrus Harmon Director | Open-market sale | −10,000 | $26.88 | $268,800 |
| Jan 15, 2026 | Kovacs Shane William Charles Officer (CH. OPERATING & FINANCIAL OFF.) | Open-market sale | −100,000 | $28.73 | $2,873,000 |
| Jan 14, 2026 | Cyrus Harmon Director | Open-market sale | −3,489 | $29.12 | $101,600 |
| Jan 14, 2026 | Myles David C. Officer (CH. DISCOV. & NON-CLIN DEV OFF) | Option exercise | +50,000 | $4.87 | $243,500 |
| Jan 14, 2026 | Myles David C. Officer (CH. DISCOV. & NON-CLIN DEV OFF) | Open-market sale | −14,997 | $28.60 | $428,914 |
| Jan 14, 2026 | Myles David C. Officer (CH. DISCOV. & NON-CLIN DEV OFF) | Open-market sale | −35,003 | $28.99 | $1,014,737 |
| Jan 13, 2026 | Kovacs Shane William Charles Officer (CH. OPERATING & FINANCIAL OFF.) | Open-market sale | −3,822 | $28.01 | $107,054 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.